Document ID: chunk:federal_register_of_legislation:F2025C00124:reg:34
Version: federal_register_of_legislation:F2025C00124
Segment Type: reg
Provision Reference: reg 34
Character Range: 52826–54293

34  Dispensing fee
 (1) For the purposes of subparagraphs 32(1)(a)(iii), (b)(ii) and (c)(iv):
 (a) the dispensing fee for the supply of an HSD pharmaceutical benefit is:
 (i) if the benefit has a drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee (within the meaning of the Approved Pharmacists Commonwealth Price Determination); or
 (ii) if subparagraph (i) does not apply—the ready‑prepared dispensing fee (within the meaning of that Determination); and
 (b) if the authorised prescriber who prescribed the benefit, instead of directing a repeated supply of the benefit, directed the supply on one occasion of a quantity or number of units of the benefit, not exceeding the total quantity or number of units that could be prescribed if the authorised prescriber directed a repeated supply, the dispensed price for the supply of the benefit includes:
 (i) only one dispensing fee; and
 (ii) only one dangerous drug fee.
Note: See section 49 of the Regulations for the circumstances in which such a supply may be directed.
 (2) For the purpose of subparagraph (1)(a)(i), the drugs and the forms for the drugs are as follows:
 (a) mycophenolic acid as a powder for oral suspension containing mycophenolate mofetil 1g per 5 mL, 165mL;
 (b) valganciclovir as a powder for oral solution 50mg (as hydrochloride) per mL, 100 mL.

Part 3A—Supply to CTG registered patients by CTG suppliers